(KTVI) – Standard treatments and a new approach may add over a year to the lives of men fighting advanced prostate cancer.
Researchers with the American Society of Clinical Oncology researchers saw the findings of a new study at a June 2014 meeting in in Chicago. Oncologist Dr. Christopher Sweeney is the lead author of the study and a doctor at the Dana-Farber Cancer Institute in Boston. He said hormone-depleting therapy has been a standard treatment since the 1950’s. But, he also said the disease can become resistant to that therapy. In the past, doctors followed that treatment with chemotherapy.
Now, he says combining the chemotherapy drug docetaxel with standard hormone-depleting therapy may extend the lives of men fighting advanced prostate cancer by as much as 18 months.
To learn more about the study, visit WebMD.com.